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Glibenclamide impairs responses 
of neutrophils against Burkholderia 
pseudomallei by reduction of 
intracellular glutathione
Chidchamai Kewcharoenwong1, Darawan Rinchai1, Arnone Nithichanon1, 
Gregory J. Bancroft2, Manabu Ato3 & Ganjana Lertmemongkolchai1
The major risk factor for melioidosis, an infectious disease caused by B. pseudomallei, is diabetes 
mellitus. More than half of diabetic melioidosis patients in Thailand were prescribed glibenclamide. 
Recent evidence demonstrates that glibenclamide reduces pro-inflammatory cytokine production by 
polymorphonuclear neutrophils (PMNs) of diabetic individuals in response to this bacterial infection. 
However, the mechanisms by which glibenclamide affects cytokine production are unknown. We found 
that PMNs from glibenclamide-treated diabetic individuals infected with live B. pseudomallei in vitro 
showed lower free glutathione (GSH) levels compared with those of healthy individuals. Glibenclamide 
decreased GSH levels and glutathione peroxidase (GPx) of PMNs after exposed to live B. pseudomallei. 
Moreover, glibenclamide reduced cytokine production and migration capacity of infected PMNs, 
whereas GSH could restore these functions. Taken together, our data show a link between the effect 
of glibenclamide on GSH and PMN functions in response to B. pseudomallei that may contribute to the 
susceptibility of diabetic individuals to B. pseudomallei infection.
Individual with diabetes are prone to increased susceptibility to infection1,2. Several infectious diseases are 
strongly associated with diabetes, including melioidosis3. Melioidosis, a serious infection caused by the 
Gram-negative bacillus Burkholderia pseudomallei, is an important clinical problem, which is endemic in 
South-East Asia and Northern Australia. The distribution of melioidosis in many tropical developing countries is 
underestimated4. It accounts for 20% of cases of community-acquired septicemia in Northeast Thailand, where it 
is associated with a mortality rate of 50%3,5 and up to 60% of melioidosis patients have preexisting type 2 diabetes 
mellitus6,7.
Animal models have shown that neutrophils play a critical role in protection against B. pseudomallei infection8,9  
and these cells are a prominent component of the blood and tissue inflammatory responses in human melioidosis10. 
We have previously explored the mechanism for increased susceptibility to melioidosis in diabetic individuals 
and found purified PMNs from diabetic individuals to be defective in phagocytosis, migration and apoptosis 
against B. pseudomallei11. Moreover, our recent report showed that the sulfonylurea drug, glibenclamide, reduces 
pro-inflammatory cytokine production by PMNs of diabetic individuals in response to bacterial infection12.
Glibenclamide rINN (glyburide USAN) is a broad-spectrum ATP-binding cassette transporter inhibitor13 and 
a K+ ATP-channel blocker shown to inhibit cryopyrin/Nalp3 inflammasome activation and proteolytic matura-
tion of IL-1β and IL-18 by caspase-114. This drug therapy is prescribed in around half of diabetics in Northeast 
Thailand15 and widely used in low to middle income settings in other countries. On the other hand, defective 
IL-12 and therefore IFN-γ production by PBMCs from diabetic individuals which leads to poor control of intra-
cellular bacterial replication is due to a deficiency in intracellular reduced glutathione (GSH) in diabetic PBMCs 
in response to B. pseudomallei and M. tuberculosis16.
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GSH, a ubiquitous sulfhydryl-containing tripeptide produced by most mammalian cells, is usually present 
as a reduced form, but GSH is converted into its oxidized form (GSSG) by stimulation such as oxidative stress. 
Therefore, a decreased ratio of reduced to oxidized glutathione is indicative of oxidative stress17. Many studies 
have showed that GSH has protective abilities against the harmful effects of oxidative stress within our body and 
enhances the functional activity of various immune cells such as natural killer (NK) cells and T cells with an 
increase in the production of pro-inflammatory cytokines resulting in inhibition in the growth of M. tuberculosis 
inside monocytes and macrophages16,18. Moreover, inhibition of GSH synthesis in PMNs results in enhanced 
mycobacterial growth17. GSH deficiency may occur in PMNs from diabetic individuals; however, to date, there 
is no information about the effects of glibenclamide on GSH in PMNs and the consequences of this for antimi-
crobial resistance.
We hypothesize that glibenclamide may interfere with the intracellular GSH levels of PMNs of diabetic indi-
viduals and lead to altered PMN functions such as cytokine production, migration and killing in response to 
B. pseudomallei infection. To address this, we determined intracellular glutathione levels of purified PMNs from 
diabetic and healthy individuals in response to B. pseudomallei. Then, we tested whether exogenous glutathione 
and N-acetylcysteine (NAC), an aminothiol and synthetic precursor of intracellular cysteine and GSH, could 
restore immune functions important in resistance to melioidosis.
Results
PMNs from diabetic individuals receiving glibenclamide therapy have impaired GSH level. It was 
previously reported that PBMC of diabetic individuals in Singapore had a deficiency in GSH, which impaired 
their cytokine response to B. pseudomallei16. To ask whether changes in GSH was also observed in PMNs, we 
determined GSH levels in PMNs purified from individuals with very poorly controlled diabetes in the melioidosis 
endemic region of North East Thailand. These diabetic individuals had all been treated with glibenclamide and 
were compared against age- and sex-matched healthy individuals. Purified PMNs from the respective groups 
were incubated in medium alone or in the presence of LPS or live B. pseudomallei, and the levels of intracellular 
GSH and GSSG were detected 1 h later. Unstimulated PMNs from diabetic individuals were found to have a sig-
nificantly lower GSH/GSSG ratio (Fig. 1a). We next confirmed the total GSH in PMNs by staining with CMFDA 
(Fig. 1b) and also found that total GSH levels in PMNs from diabetic individuals treated with glibenclamide were 
significantly lower, while those in PMNs from individuals given other or no treatments (total n = 4) including 
metformin (n = 1), insulin (n = 2), and no treatment (n = 1) were significantly higher than those of healthy con-
trols. Also in vitro, PMNs from healthy individuals pre-treated with glibenclamide but not metformin showed sig-
nificantly reduced total GSH when compared with untreated cells (Fig. 1c). These data demonstrated that PMNs 
from diabetic individuals with poor glycemic control receiving glibenclamide therapy were intrinsically impaired 
in their intracellular GSH levels and this persisted when stimulated with LPS or infected with B. pseudomallei.
Glibenclamide decreases intracellular GSH level of PMNs. Since our previous data showed that dia-
betic individuals who had been treated by glibenclamide had impaired cytokine production12, we next deter-
mined whether the low GSH levels in B. pseudomallei-infected PMNs from diabetes was a result of glibenclamide 
Figure 1. PMNs from diabetic individuals receiving glibenclamide therapy show lower glutathione 
level. (a) Purified PMNs from both healthy (n = 3) and diabetic individuals receiving glibenclamide therapy 
(n = 3) were co-cultured with B. pseudomallei in MOI of 1:1 for 1 h, and then levels of intracellular GSH 
and GSSG were determined in cell lysates. Data are showed as GSH/GSSG ratio by median with range. 
Asterisks indicate significant differences of all conditions between healthy and DM individuals by Two Way 
ANOVA. (b) Purified PMNs from both healthy (n = 8), and diabetic individuals receiving other drug therapy 
(DM-others, n = 4) and diabetic individuals receiving glibenclamide therapy (diabetic-GB, n = 4) were co-
cultured with B. pseudomallei in MOI of 1:1, and then total glutathione was stained with CMFDA at 18 h for 
medium (Med) and B. pseudomallei (Bps) infection. (c) Purified PMNs from healthy individuals (n = 3) were 
treated by glibenclamide (50 μ M) or metformin (50 μ M) for 1 h. Drug-treated PMNs were incubated with 
B. pseudomallei (MOI 1:1) for 1 h and then total glutathione was stained with CMFDA at 18 h for medium 
(Med) and B. pseudomallei (Bps) infection and mean fluorescence intensity (MFI) was analyzed by flow 
cytometry. Statistical analysis was performed using One Way ANOVA. Data are expressed as median with 
range. ***P < 0.001, **P < 0.01, and *P < 0.05. No asterisk, non significant.
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treatment. Purified PMNs from healthy individuals were pre-treated with glibenclamide before co-culture 
with either LPS or live B. pseudomallei. After incubation for 1 h, PMNs were collected to detect intracellular 
GSH and GSSG levels. We found that glibenclamide alone significantly reduced GSH/GSSG ratio of PMNs in 
a dose-dependent manner (Fig. 2). No significant effect of glibenclamide was observed on production of reac-
tive oxygen species (ROS) perhaps due to production of superoxide and hydrogen peroxide depleting GSH19,20 
(Supplementary Fig. S1).
Since it was reported that glutathione peroxidase (GPx) activity was decreased in the cytosol of PMNs 
from diabetic individuals compared to those from controls21, GPx and glutathione reductase (GR) activities 
were investigated in the same conditions. We found that glibenclamide also significantly reduced GPx activity 
(Supplementary Fig. S2), but did not affect GR activity (Supplementary Fig. S3). Together, these data demon-
strated that glibenclamide reduced intracellular GSH level and GPx activity but not ROS production and GR 
activity of PMNs in response to LPS stimulation or B. pseudomallei infection.
In vitro addition of GSH improves IL-8 production of PMNs from diabetic individuals receiv-
ing glibenclamide therapy. Cytokine production by neutrophils is an important component of innate 
immunity which is reduced in diabetic individuals12. To ask whether exogenous addition of GSH could restore 
the impaired cytokine response of glibenclamide-treated PMNs, purified PMNs from healthy individuals were 
pre-treated with glibenclamide alone over a range of 3, 12 and 50 μ M or combined with GSH and then infected 
with B. pseudomallei for 18 h. PMNs treated with glibenclamide alone showed a significant, dose dependent 
reduction IL-1β and IL-8 levels in response to B. pseudomallei infection in vitro, in agreement with what has been 
previously reported12 whereas GSH significantly enhanced the production of both cytokines (Fig. 3a). Moreover, 
our data showed that GSH depletion by diethylmaleate (DEM) treatment reduced IL-1β production of PMNs 
in response to B. pseudomallei (Fig. 3b). Under these conditions, addition of GSH alone or DEM alone, in the 
absence of bacteria, did not induce detectable cytokine production (data not shown). These data suggested that 
exogenous GSH could restore the impaired cytokine responses of glibenclamide-treated PMNs.
The above observations led us to determine the effect of N-acetylcysteine (NAC), an aminothiol and synthetic 
precursor of intracellular cysteine and GSH, on cytokine production of PMNs from diabetic individuals who had 
been treated by glibenclamide. NAC, a prodrug that supplies bioavailable cysteine necessary for the replenishment 
of GSH, is routinely administered clinically to overcome pharmacologically induced GSH deficiency22,23. Either 
GSH or NAC was added exogenously to the cells and the cytokine levels were monitored after B. pseudomallei 
infection. NAC significantly enhanced both IL-1β and IL-8 production by PMNs from both healthy and diabetic 
individuals in a dose-dependent manner. However, there was a trend for IL-1β production by cells of diabetic 
individuals to be increased by GSH but this was not statistically significant (Fig. 4). Treatment with GSH or NAC 
alone has no effect. However the magnitude of IL-1β production of PMNs from diabetic individuals was still low. 
Together, these findings indicated that both GSH and NAC could improve cytokine production, especially IL-8, 
of PMNs from diabetic individuals in response to B. pseudomallei infection.
Glutathione improves impaired migration activity of PMNs from glibenclamide-treated dia-
betic individuals. Since glibenclamide reduced IL-8 production, which plays a role in the induction of PMN 
infiltration, purified PMNs from both diabetic and healthy individuals were investigated for transmigration in 
response to B. pseudomallei infection over a range of 0.3, 3 and 10 MOIs. We found that the number of transmi-
grated PMNs to B. pseudomallei of diabetic individuals who had been treated with glibenclamide was significantly 
Figure 2. Glibenclamide decreases intracellular glutathione (GSH) level of PMNs from healthy individuals. 
Purified PMNs from healthy individuals (n = 3) were treated by glibenclamide (GB, 3, 12 and 50 μ M)  
for 1 h. Drug-treated PMNs were incubated with 1 μ g/ml LPS or B. pseudomallei (MOI 1:1) for 1 h and then 
the cells were collected for intracellular GSH and GSSG detection. Statistical analysis was performed using 
Two Way ANOVA comparing each GB treatment group with no GB treatment of each group. The results are 
expressed as GSH/GSSG ratio by as median with range from 3 independent experiments, and samples were 
assayed in duplicated. *P < 0.05, **P < 0.01, ***P < 0.001. No asterisk, non significant.
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lower than those of healthy controls (Fig. 5a). Further, glibenclamide-treated PMNs from healthy individuals 
also showed significantly decreased transmigration when compared with non-treated cells (Fig. 5b) in response 
not only to B. pseudomallei but also other bacteria; S. enterica serovar Typhimurium and E. coli. To test the effect 
of GSH on the migration capacity of PMNs, purified PMNs from diabetic and healthy individuals were supple-
mented with GSH or NAC prior to exposure to B. pseudomallei or recombinant IL-8. Diabetic PMNs treated with 
GSH and NAC showed significant improvement in their migration responses to bacteria and recombinant IL-8 
(Fig. 5c,d). Together, these data suggested that glibenclamide impaired PMN migration of diabetic individuals 
while GSH and NAC restored this function.
In vitro addition of glutathione affects phagocytosis and killing of PMNs from diabetic individu-
als receiving glibenclamide therapy. To further examine the effect of GSH and NAC on the antimicrobial 
functions of impaired PMNs, purified PMNs from either healthy individuals or diabetics with poor glycemic con-
trol were exposed to live B. pseudomallei in vitro and the extent of phagocytosis and killing were determined by 
counting intracellular bacteria. The percentage of initial inoculum, which measures phagocytic activity, showed 
that GSH supplementation partially increased phagocytosis of the bacteria by PMNs (Fig. 6a) and both GSH and 
NAC induced PMN mediated killing of B. pseudomallei (Fig. 6b) in diabetic individuals, while supplementation 
did not affect PMNs from healthy controls. However, the supplementation by GSH and NAC could only show 
limited improvement of phagocytosis and killing and could not restore these functions of PMNs from diabetic 
individuals who had been treated by glibenclamide to that of healthy controls.
Discussion
Diabetic individuals commonly show increased susceptibility to bacterial infections24–26. In Thailand, type 2 
diabetes mellitus is the most common underlying condition associated with melioidosis. Two main possible 
mechanisms have been proposed to explain the high susceptibility of diabetic individuals under hyperglycemic 
conditions in response to B. pseudomallei infection. First, diabetic individuals in Singapore had a defective IL-12 
and therefore IFN-γ production by PBMCs leading to poor control of intracellular bacterial replication and the 
impairment response to a deficiency in intracellular reduced glutathione (GSH) in diabetic PBMCs in response 
to B. pseudomallei16. Second, we previously demonstrated that polymorphonuclear neutrophils (PMNs) from 
diabetic individuals had impaired functions, including phagocytosis, migration, and apoptosis, encountered 
to B. pseudomallei infection11. We proposed this is at least in part due to a pattern of glibenclamide-induced 
immunosuppression, wherein IL-1β and IL-8, proinflammatory cytokines, belonging to PMNs were significantly 
Figure 3. Glutathione enhances cytokine production of glibenclamide-treated PMNs. (a) Purified PMNs 
from healthy individuals were treated by glibenclamide (GB, 3, 12 and 50 μ M) and glutathione (GSH, 3 and 
12 mM) for 1 h. After treatment PMNs were infected with B. pseudomallei (MOI 0.3:1) for 18 h, the supernatants 
were collected. Statistical analysis was performed using One Way ANOVA comparing each GSH treatment 
group with no GSH of each GB treatment group and paired t test comparing each GB alone group with Bps 
alone. (b) Purified PMNs were treated by diethyl maleate (DEM, 15, 30 and 60 μ M) for 1 h. Treated PMNs 
were infected with B. pseudomallei (MOI 0.3) and the supernatant was collected at 18 h. Statistical analysis was 
performed using One Way ANOVA comparing each DEM treatment group with no DEM treatment group 
(0). The results are expressed as median with range, and samples were assayed in duplicate from 4 independent 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
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decreased in diabetic individuals who have been treated by either glibenclamide alone or combination with 
metformin12.
More than half of all diabetic melioidosis patients in Thailand were prescribed glibenclamide, and those on 
this oral hypoglycemic agent had a survival benefit compared with nondiabetic melioidosis patients and with 
diabetic melioidosis patients on other diabetic medications, such as metformin and insulin15,20. These patients are 
suggested to be less likely to undergo severe hyper-inflammatory responses in septic melioidosis, which may be 
explained, at least in part, by our data suggesting that glibenclamide could decrease GSH and IL-1β production 
of PMNs. These might be due to the reduction of GSH linked to the effect of glibenclamide during melioidosis. 
Nevertheless, glibenclamide treatment with poor glycemic control may place diabetic patients at a disadvantage 
for onset or a recurrence of B. pseudomallei infection. Glibenclamide is a widely used antidiabetic drug not only 
in Thailand but also in other low- and middle-income countries27 but notably not in Singapore. It is still used 
with elderly diabetic individuals in these countries, though the WHO model list of essential medicines (2015) 
reported that it is not suitable for those aged above 60 years28. The use of glibenclamide is likely linked to poverty 
and poor economic conditions, whereas some upper-income countries use other drugs of choice. The effect of 
glibenclamide was attributed to its anti-inflammatory nature, as it had been shown to be able to inhibit NLRP3 
inflammasome activation20. However, there is no evidence on GSH deficiency and its potential effects on may 
occur in PMN and whether this is linked to glibenclamide. Thus, our present study aimed to determine the effect 
of glibenclamide on the intracellular GSH level from PMNs of diabetic individuals and the impact of this on PMN 
function.
Our findings indicate that diabetic individuals who had been treated by glibenclamide show impaired cytokine 
production and migration activity of PMNs in response to B. pseudomallei by reduction of intracellular GSH 
levels and GPx activity. However, in streptozotocin-induced diabetic rat models, decreased levels of GSH in the 
brain, muscle, pancreatic β -cells and blood have been reported. In addition, the activity of antioxidant enzymes 
such as GPx, among others, has been found to be down-regulated29–32. Also we found that PMNs from healthy 
controls incubated with glibenclamide reduced intracellular GSH so the reduction of GSH may concern both 
poor glycemic control and drug treatment in diabetic individuals. Not only our data in PMNs, but a recent study 
in PBMCs obtained from poor glycemic control diabetes also showed low intracellular GSH levels are critical in 
allowing better initiation of the intracellular infection and provide an explanation for the increased susceptibility 
of diabetic individuals to melioidosis. The low intracellular GSH/GSSG ratio could also affect disease progression 
and outcome16. Our data also showed that depletion of GSH in PMNs supported the conclusion that GSH defi-
ciency contributes to decreased IL-1β production.
Figure 4. Glutathione and N-acetylcysteine enhances IL-8 production of PMNs from diabetic individuals 
receiving glibenclamide therapy. The concentrations of IL-8 and IL-1β were determined by ELISA. PMNs 
from healthy (n = 7) and diabetic patients (n = 4) were pre-treated by glutathione (GSH) or N-acetylcysteine 
(NAC) at varied concentrations (6.25, 12.5, 25 and 50 mM) and then infected with B. pseudomallei in MOI of 
0.3:1. The supernatants were collected at 18 h. Asterisks indicate significant differences between non-treated 
and treated conditions by One Way ANOVA and expressed as median with range, and samples were assayed in 
duplicate. ***P < 0.001, **P < 0.01, and *P < 0.05. No asterisk or ns, non significant. ND, not determine.
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In contrast, we found that PMNs from diabetic individuals with poor glycemic control but treated by insu-
lin had increased GSH in response to B. pseudomallei compared with healthy or glibenclamide-treated diabetic 
individuals. This result was consistent with a previous study in streptozocin (STZ)-induced diabetic rats shown 
that Insulin restored hepatic glutathione concentrations to normal levels33. The data implies that reduction of 
intracellular GSH in PMNs is mainly caused by glibenclamide treatment.
Another study in mouse models of sepsis has reported that migration of PMNs to a site of infection (the 
skin) and to a distant site (the lung) is differently regulated, and optimal GSH levels are important for an efficient 
response to sepsis34. We found that normal GSH status is essential for proper PMN migration in response to 
live bacteria, in that GSH impairment with glibenclamide decreases PMN transmigration after co-cultured with 
B. pseudomallei. Small but statistically significant changes in PMN numbers have been implicated in altered sus-
ceptibility to infection with other pathogens; for example, in the context of M. tuberculosis, risk of TB infection 
was inversely and independently associated with peripheral blood neutrophil count in contacts of patients diag-
nosed with pulmonary TB35. Moreover it has been demonstrated in Ifnar1−/− mice infected with M. tuberculosis 
that a small reduction of PMN recruitment to the site of infection also showed a significant decrease in survival 
rate36. Studies in humans and mice have identified PMNs and PMN-recruiting chemokines at sites of B. pseudom-
allei infection, particularly in association with abscess formation8,37. Clinical susceptibility and the development 
of severe bacteremic disease are often associated with diabetes mellitus6, a condition in which PMN migration 
is known to be impaired. This small difference of PMN numbers migrating to the infected site, together with 
impairment of other cell functions, might lead to increasing susceptibility to bacterial infection.
This is an important distinction, since the role of glibenclamide in intracellular GSH is uncertain. We believe 
that changes in GSH levels due to glibenclamide, represent a novel and potentially important effect of the dia-
betic drug on innate defense mechanism adopted by human PMNs to control B. pseudomallei infection through 
Figure 5. Glutathione and N-acetylcysteine improves impaired migration activity of PMNs. (a) Numbers 
of transmigrating PMNs of diabetic (n = 4) comparing with healthy (n = 4) individuals. Purified PMNs were 
added into the upper wells and co-cultured with live B. pseudomallei put into the lower wells. After co-culture 
for 1 h, transmigrating PMNs were counted by flow cytometry. Asterisks indicate significant differences 
between healthy and DM individuals at the same concentrations. (b) Purified PMNs from healthy individuals 
(n = 3) were treated by 50 μ M glibenclamide (GB) before infection with B. pseudomallei, S. enterica serovar 
Typhimurium (Sal), and E. coli at MOI of 10:1. Asterisks indicate significant differences between glibenclamide 
treatment and medium alone in the same conditions by paired t test. (c) Purified PMNs from healthy (n = 3) 
and diabetic (n = 3) individuals were treated by 12.5 mM glutathione or 12.5 mM NAC before addition to the 
upper wells and co-cultured with B. pseudomallei at MOI of 3:1 or (d) with 40 ng/ml of recombinant human 
IL-8 (rIL-8). Asterisks indicate significant differences between medium control and not-treated (0) or between 
not-treated and other conditions. P values were calculated by using One Way ANOVA. Data are expressed 
as median with range, and samples were assayed in duplicate. No asterisk or ns; non significant, *P < 0.05, 
**P < 0.01.
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GSH redox. The explanation of GSH reduction by glibenclamide treatment may be due to the following possible 
mechanisms: 1) we found that glibenclamide did not affect the regenerated GSH cycle by the enzyme GR which 
performs the reduction of GSSG to GSH, and oxidation of NADPH to NAD+17, but it reduced GPx levels which 
performs the reduction of hydrogen peroxide to water, while linking two GSH molecules together by a disulfide 
bridge to form GSSG. 2) Glutathione-S-transferase omega 1 (GSTO1) is a recently characterized cysteine con-
taining enzyme with the capability to bind and release GSH in vitro38. GSTO1 was found to associate with ASC, a 
component of the inflammasome, suggesting that it might play a role in NLRP3 and AIM2 inflammasome signal-
ling and could indeed be a target of diarylsulfonylurea containing compounds called Cytokine Release Inhibitory 
Drugs (CRIDs) that inhibited the post-translational processing of IL-1β 39. Thus, glibenclamide might affect these 
mechanisms and cause reduced intracellular GSH, which in turn leads to decrease bactericidal activity of PMNs 
from diabetic individuals.
Figure 6. Glutathione and N-acetylcysteine affects bacteria uptake and bactericidal activity of PMNs from 
diabetic individuals. (a) Purified PMNs from healthy (n = 5) and diabetic (n = 4) individuals were treated by 
12.5 mM glutathione or 12.5 mM NAC before co-culture with live B. pseudomallei at an MOI of 1:1 for 30 min, 
and extracellular organisms were killed by incubation with 250 μ g/ml kanamycin for another 30 min before 
the PMNs were lysed for bacterial counting (initial inoculum time) and after 3 h. Intracellular bacteria were 
quantified by colony plating at the indicated time points, and the results are expressed as percentages of the 
initial inocula for each individual, which were calculated by dividing the number of recovered bacteria by the 
total number of B. pseudomallei cells added. (b) %Killing was calculated by dividing the decreased number of 
bacteria at 3 h by the number of bacteria at initial inoculum time. Asterisks indicate significant differences and  
P values were calculated by using One Way ANOVA. Data are expressed as median with range, and samples 
were assayed in duplicate. No asterisk or ns; non significant, *P < 0.05, **P < 0.01.
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Moreover, we experimented with exogenous GSH and N-acetylcysteine (NAC) and whether they could restore 
immune functions. We found that the addition of GSH or NAC significantly boosted both cytokine production 
and migratory functions of PMNs from diabetic individuals who had been treated by glibenclamide. However, 
GSH restored the magnitude of IL-1β less than IL-8, perhaps because of pre-existing impairment of IL-1β in 
PMNs of poor glycemic control diabetic individuals12. Either GSH or NAC also enhanced the direct antimicrobial 
functions of PMNs from diabetic individuals who had been treated with glibenclamide or in combination with 
metformin. Differently from cytokine production and recruitment, GSH could not fully restore the phagocytic 
activity of PMNs from diabetic individuals to those from healthy controls. It might imply that GSH had only 
a partial contribution to the altered phagocytic activity of PMNs from diabetic individuals which may be also 
affected by preexisting defects of poor glycemic control11 through oxygen uptake40 and membrane synthesis41. In 
contrast, both GSH and NAC increased the killing activity of diabetic PMN.
In conclusion, we have shown that glibenclamide reduced intracellular GSH concentrations in PMNs from 
diabetic individuals with poor glycemic control, resulting in a significant decrease in IL-1β and IL-8 production of 
PMNs in response to B. pseudomallei infection. This in turn impairs the migratory capacity of PMN from diabetic 
individuals as compared with healthy controls. Our work has therefore revealed a new link between the effect of 
glibenclamide on GSH and PMN functions in response to B. pseudomallei that may affect host susceptibility to 
B. pseudomallei infection in diabetic individuals. However, there is clearly a delicate balance between host defense 
and inflammation. GSH reduction, which is often associated with sepsis42, might be detrimental by decreasing 
PMN recruitment and so increasing the risk of infection but conversely reduce the extent of PMN mediated 
organ damage. We are not aware of current pharmacological approaches which can selectively inhibit the path-
ogenic aspects of inflammation without potentially interfering with the benefits of phagocyte recruitment and 
activation. One multicenter trial found that direct IL-1 blockade does not improve survival in all-cause sepsis43. 
It is unclear whether any benefit would be seen were glibenclamide started following the onset of infection in 
nondiabetic patients. However, the central role of GSH in both monocyte16 and PMNL responses to B. pseudom-
allei strengthens the need to consider whether adjunctive treatment with thiol antioxidants and GSH-repleting 
agents might be of benefit in individuals from low income countries where glibenclamide is the only option for 
management of Type II diabetes. A previous study showed that oral NAC supplementation in diabetic individuals 
is only sufficient to increase intracellular GSH content in blood cells but not sufficient to improve bactericidal 
activity in monocytes44. However, their study showed the complication of only poor glycemic control in diabetic 
patients and excluded diabetic individuals who had glibenclamide treatment. These agents might help reorient 
cytokine production and migration activity of PMNs from glibenclamide treated individuals in a way that is more 
favorable to the host. In a mouse model, NAC enhanced PMN infiltration in the site of infection improved the 
survival outcome34. This strategy could be combined with supplementation with glutamine, which seems to play 
an important role in PMN functions45. Given the relatively low costs of these treatments, they may be considered 
as preventive supplements in diabetics with poor glycemic control at high risk of exposure B. pseudomallei in 
endemic areas.
Methods
Blood samples. We enrolled 24 diabetic and 31 healthy Thai individuals. All individuals were defined here 
as aged over 35 years and matched by sex and age11. None of the individuals had any signs of acute infectious 
disease in the three months prior to sampling. The healthy control group consisted of individuals with nor-
mal fasting blood glucose levels (3.9–6.2 mmol/L) and normal glycosylated hemoglobin A1c (HbA1c) levels 
(< 6.5%). HbA1c was detected by immunoturbidimetric assay and the results were reported following the 
National Glycohemoglobin Standardization Program (NGSP). The healthy individuals were recruited from both 
blood bank donors and healthy university staff, who live in the same endemic area as diabetic individuals. The 
diabetic individuals involved in this study had all been treated with glibenclamide either alone or in combination 
with metformin with very poor glycosylated hemoglobin A1c (HbA1c) levels (> 8.5%)11, unless stated other-
wise. All diabetic individuals were treated at the Outpatient Department, Khon Kaen Hospital and Khon Kaen 
Primary Medical Service. The exclusion criteria for both healthy and diabetic individuals were impaired renal 
function which causes secondary immunosuppression and is itself a separate risk factor or melioidosis, defined 
by a serum creatinine level of ≥ 0.11 mmol/L. The sample collection and analysis of all samples was approved by 
the Khon Kaen University Ethics Committee for Human Research and the Khon Kaen Hospital Ethics Committee 
(HE470506). The study was carried out in accordance with the approved guidelines and all subjects provided 
written informed consent. Each experiment was performed with both healthy and matching DM subjects, gener-
ally one healthy versus one matching DM subject, unless stated otherwise.
Microorganisms. B. pseudomallei K96243 strain was grown to mid-logarithmic phase at 37 °C in 
Luria-Bertani (LB) broth. Bacterial growth was assessed by measuring the optical density at 600 nm. Generally, 
an absorbance index of 1 was equivalent to109 CFU/mL of bacteria and the number of viable bacteria 
(colony-forming units) in inocula was determined by retrospective plating of serial ten-fold dilutions on LB agar. 
Live B. pseudomallei was handled under the US Centers for Disease Control regulations for research at biosafety 
containment level 3. Salmonella enterica serovar Typhimurium ATCC 13311 and Escherichia coli ATCC 25422 
were obtained from the Microbial Culture Collection Center, Thailand, grown overnight in LB broth at 37 °C and 
enumerated as above.
Isolation of PMNs. We isolated PMNs from heparinized venous blood by dextran sedimentation and 
Ficoll-Paque centrifugation, as previously described11, and the resulting cell preparation was confirmed to consist 
of > 95% PMNs by flow cytometry and by CD14 staining. The morphology of PMNs was also determined by 
Giemsa staining and microscopy, and the cell viability was > 98%, as determined by trypan blue exclusion.
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Detection of intracellular GSH and GSSG concentration by colorimetric assay. In some experi-
ments, purified PMNs at a concentration of 1 × 106 cells in RPMI 1640 were pre-treated for 1 h with varied con-
centrations of glibenclamide (Sigma) which are comparable to human blood concentrations achieved following 
a standard 20 mg oral dose46 before co-culture at 37 °C, 5% CO2 for 1 h with live B. pseudomallei at a multiplicity 
of infection (MOI) of 1:1 or with 1 μ g/ml of LPS (from Escherichia coli, Sigma). Intracellular GSH and oxidative 
glutathione (GSSG) concentrations in PMNs were determined using a Glutathione Colorimetric Detection Kit 
(Arbor Assays) according to the manufacturer’s instructions.
Determination of intracellular GSH level by 5-chloromethylfluorescein-diacetate (CMFDA). 
Purified PMNs at a concentration of 2.5 × 106 cells/ml in RPMI 1640 (Gibco) were incubated at 37 °C, 5% CO2 for 
18 h with live B. pseudomallei at a multiplicity of infection (MOI) of 1:1. In some experiments, the following rea-
gents were added to PMNs for 1 h prior to infection. The reagents were 50 μ M glibenclamide in DMSO (Sigma), 
and 50 μ M metformin in water for injection (Sigma). Then, cells were stained by 0.5 μ M CMFDA (Invitrogen) to 
detect total GSH (specificity 95%)47 according to the manufacturer’s instructions and mean fluorescence intensity 
(MFI) was analyzed by flow cytometry (FACSCalibur; BD Biosciences) for 10,000 events gated on the granulocyte 
population.
Measurement of cytokine production. Unless stated otherwise, purified PMNs at a concentration of 
2.5 × 106 cells/ml in RPMI 1640 culture medium (Gibco) with 10% fetal bovine serum were incubated at 37 °C, 5% 
CO2 for 18 h with B. pseudomallei at a multiplicity of infection (MOI) of 0.3:1. In some experiments, the following 
reagents were added to PMNs for 1 h prior to infection. The reagents were varied concentrations of glibencla-
mide in DMSO (Sigma), diethyl maleate (DEM) in ethanol (Sigma) and both GSH (Sigma) and N-acetylcysteine 
(NAC) in water for injection (Sigma). The supernatants were stored at − 80 °C until the cytokine assay. When 
indicated, we assessed IL-1β and IL-8 concentration in the supernatant of PMN cultures in duplicate by ELISA 
(BD Biosciences) according to the manufacturer’s instructions.
Determination of PMN migration. Purified PMNs at a concentration of 5 × 106 cells/ml were incubated 
in the upper chamber of 3-μ m-pore-size Transwell plates (Corning Life Sciences), B. pseudomallei at an MOI 
of 0.3:1, 3:1, or 10:1 was placed in the lower 0.5 ml chamber, and the plates were incubated at 37 °C for 1 h. 
Transmigrated PMNs in the lower chamber with reference beads were counted by flow cytometry (FACSCalibur; 
BD Biosciences) for 10,000 events gated on the granulocyte population. The absolute count of transmigrated 
PMNs was calculated by relating the number of cells counted to the total number of bead events. In some exper-
iments, purified PMNs were pre-treated with 50 μ M glibenclamide (Sigma), 12.5 mM GSH (Sigma) and 25 mM 
NAC (Sigma) at 37 °C for 1 h prior to the test for migration.
Determination of PMN mediated killing of B. pseudomallei. Purified PMNs were treated by 12.5 mM 
glutathione or 12.5 mM NAC before co-cultured with live B. pseudomallei at an MOI of 1:1 for 30 min, and extra-
cellular organisms were killed by incubation with 250 μ g/ml kanamycin for another 30 min before the cells were 
lysed for bacterial counting (initial inoculum time) and after 3 h. Intracellular bacteria were quantified by colony 
plating at the indicated time points, and the results are expressed as percentages of the initial inocula for individ-
uals, which were calculated by dividing the number of recovered bacteria by the total number of B. pseudomallei 
cells added. (B) %Killing was calculated by dividing the decreased number of bacteria at 3 h by the number of 
bacteria at initial inoculum time.
Statistics. Statistical analysis (One Way and Two Way ANOVA with post-test Bonferroni) was performed by 
using Graphpad PRISM statistical software version 5 (Graphpad 5). P values ≤ 0.05 were taken to be significant. 
The power of each test was calculated by post-hoc power analysis with 95% confidence interval and more than 
80% was acceptable for all experiments.
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